Consensus Singular Genomics Systems, Inc.

Equities

OMIC

US82933R1005

Real-time Estimate Cboe BZX Other stock markets 07:11:52 29/04/2024 pm IST			5-day change	1st Jan Change
0.399 ^USD	-1.29%		-1.12%	-14.04%

20/03	UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating	MT
18/03	Transcript : Singular Genomics Systems, Inc., Q4 2023 Earnings Call, Mar 18, 2024

Evolution of the average Target Price on Singular Genomics Systems, Inc.

Price target over the last 5 years

History of analyst recommendation changes

820da9b7e9e194a9c75fb130bca.mhrHuXWMtngwm9BoWC3LJvidZQu67gWUwSY6KFRXCF0.z1aS6gfYwDVE-qksKlyGZ7LQUFnQuUv5-GtTZzljTgTJI_OKRtjiEmTYlQ~f7d33bc53db55ab10d0e0e1834d9a8a7

Analyst Recommendations on Singular Genomics Systems, Inc.

UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating	20/03	MT
Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.85 From $0.95, Maintains Neutral Rating	22/01	MT
UBS Adjusts Singular Genomics Systems Price Target to $0.40 From $0.90, Maintains Neutral Rating	12/23/12	MT
UBS Adjusts Singular Genomics Systems Price Target to $0.90 From $1, Maintains Neutral Rating	10/23/10	MT
Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $1 From $1.15, Maintains Neutral Rating	10/23/10	MT
UBS Adjusts Price Target on Singular Genomics Systems to $1 From $1.25, Maintains Neutral Rating	10/23/10	MT
UBS Adjusts Singular Genomics Systems Price Target to $1.25 From $2.25, Maintains Neutral Rating	10/23/10	MT
UBS Adjusts Singular Genomics Systems Price Target to $2.25 From $2.50, Maintains Neutral Rating	06/23/06	MT
Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $3 From $3.50, Maintains Neutral Rating	08/22/08	MT
UBS Adjusts Singular Genomics Systems Price Target to $2.50 From $4.50, Maintains Neutral Rating	08/22/08	MT
UBS Downgrades Singular Genomics Systems to Neutral From Buy, Adjusts Price Target to $4.50 From $10	17/22/17	MT
JPMorgan Downgrades Singular Genomics Systems to Neutral From Overweight	10/22/10	MT
BofA Securities Double Downgrades Singular Genomics Systems to Underperform From Buy; Price Target is $3	10/22/10	MT
Goldman Sachs Downgrades Singular Genomics Systems to Neutral From Buy; Price Target is $3.50	10/22/10	MT
Goldman Sachs Adjusts Singular Genomics Systems Price Target to $5 From $9.50, Maintains Buy Rating	14/22/14	MT
UBS Adjusts Singular Genomics Systems Price Target to $10 From $15, Maintains Buy Rating	12/22/12	MT
Goldman Sachs Adjusts Singular Genomics Systems Price Target to $9.50 From $11, Maintains Buy Rating	11/22/11	MT
Goldman Sachs Adjusts Singular Genomics Systems' Price Target to $11 from $17, Keeps Buy Rating	13/22/13	MT
UBS Adjusts Singular Genomics Systems Price Target to $15 From $25, Maintains Buy Rating	03/22/03	MT
BofA Securities Upgrades Singular Genomics Systems to Buy From Neutral, Sets $21 Price Target	07/22/07	MT
UBS Adjusts Singular Genomics Systems Price Target to $25 From $32, Maintains Buy Rating	06/22/06	MT
SINGULAR GENOMICS : UBS Adjusts Price Target on Singular Genomics Systems to $32 From $35, Maintains Buy Rating	15/21/15	MT
SINGULAR GENOMICS : BofA Securities Starts Singular Genomics Systems at Neutral With $26 Price Target	21/21/21	MT
SINGULAR GENOMICS : Cowen Starts Singular Genomics Systems at Outperform	21/21/21	MT
ANALYST RECOMMENDATIONS : BT Group, FIGS, Intel, Ocado, Rio Tinto...	21/21/21